From the Guidelines
The recommended dose of Tedizolid (Sivextro) for acute bacterial skin and skin structure infections is 200 mg administered once daily for 6 days. This recommendation is based on the most recent and highest quality study available, which compared the efficacy of 6 days of tedizolid with 10 days of linezolid or tedizolid for the treatment of cellulitis, and found similar clinical responses in both groups 1. The 6-day course of tedizolid is a convenient option for patients, as it is shorter than many other antibiotics for similar infections, which typically require 10-14 days of treatment.
Key Points
- Tedizolid can be administered orally or intravenously, with the ability to switch between these routes based on clinical needs.
- The oral tablet can be taken with or without food, offering flexibility for patients.
- For intravenous administration, the drug should be infused over 1 hour.
- No dose adjustment is needed when switching between oral and IV formulations due to the drug's equivalent bioavailability.
- Tedizolid is primarily effective against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).
- Patients with mild to moderate hepatic or renal impairment do not require dose adjustments, though caution should be exercised in severe cases as limited data exists for these populations 1.
From the FDA Drug Label
The recommended dosage of SIVEXTRO is 200 mg administered once daily for six (6) days either orally (with or without food) or as an intravenous (IV) infusion in patients 12 years of age or older. Table 1: Dosage of SIVEXTRO Infection|Route|Dosage|Frequency|Infusion Time|Duration of Treatment Acute Bacterial Skin and Skin Structure Infections (ABSSSI)|Intravenous|200 mg|Once daily|1 hour|6 days Acute Bacterial Skin and Skin Structure Infections (ABSSSI)|Oral|200 mg|Once daily|Not Applicable|6 days
The recommended dose of Tedizolid (Sivextro) for bacterial infections is 200 mg administered once daily, and the treatment duration is 6 days. This can be given either orally or as an intravenous infusion in patients 12 years of age or older 2.
- The dosage is the same for both oral and intravenous routes.
- The treatment duration is 6 days for acute bacterial skin and skin structure infections (ABSSSI).
From the Research
Recommended Dose and Treatment Duration of Tedizolid
- The recommended dose of Tedizolid (Sivextro) for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) is 200 mg once daily 3, 4, 5, 6, 7.
- The treatment duration of Tedizolid for ABSSSIs is 6 days 3, 4, 5, 6.
- Tedizolid has been shown to be non-inferior to linezolid in the treatment of ABSSSIs, with a similar clinical response rate and a lower risk of gastrointestinal adverse events and bone marrow suppression 6.
- The pharmacokinetics of Tedizolid allow for once-daily dosing and easy intravenous-to-oral conversion, making it a convenient treatment option 3, 7.
Efficacy and Safety of Tedizolid
- Tedizolid has demonstrated potent in vitro activity against multidrug-resistant gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) 3, 7.
- Clinical trials have shown that Tedizolid is well-tolerated, with a similar risk of treatment-emergent adverse events compared to linezolid 6, 7.
- Tedizolid has a lower risk of nausea, vomiting, and abnormal neutrophil count compared to linezolid 6.
Special Populations and Potential Adverse Effects
- Tedizolid can be used in special populations, including adolescents, older adults, obese individuals, and patients with diabetic foot infections 5.
- The potential adverse effects of Tedizolid include nausea, vomiting, and abnormal neutrophil count, although these are less common compared to linezolid 6, 7.